Results 171 to 180 of about 417,013 (351)

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger   +6 more
wiley   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch   +9 more
wiley   +1 more source

Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria

open access: gold, 2012
Laisa Socorro Briongos-Figuero   +8 more
openalex   +2 more sources

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka   +7 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

Epidemiology of fungal urinary tract infections: A retrospective case series. [PDF]

open access: yesNew Microbes New Infect
Khateb AM   +4 more
europepmc   +1 more source

Treatment and Clinical Outcomes of Urinary Tract Infections Caused by KPC-Producing Enterobacteriaceae in a Retrospective Cohort

open access: green, 2012
Bryan Alexander   +5 more
openalex   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Home - About - Disclaimer - Privacy